Abstract: The present disclosure relates to controlling drug release in cross-linked poly(valerolactone) based matrices. In one aspect, the compounds or pharmaceutically acceptable salts thereof include a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol (PEG) copolymer. In some embodiments, at least a portion of allylvalerolactone residues within the copolymer are crosslinked with a crosslinker. In some embodiments, the compound has a polydispersity index of less than or equal to 1.5. In one aspect, a method is described herein, comprising: (a) polymerizing valerolactone residues, allylvalerolactone, and polyethylene glycol residues in the presence of a non-metal catalyst via a ring opening polymerization to produce a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer; (b) crosslinking the poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer with a crosslinker; and (c) loading a drug into the crosslinked copolymer.

Abstract: Oil compositions and compositions thereof that can form nanoemulsions or microemulsions are disclosed. Such compositions and compositions thereof can be useful for antimicrobial properties and be used to treat or prevent microbial infections.

Abstract: The present disclosure relates to controlling drug release in cross-linked poly(valerolactone) based matrices. In one aspect, the compounds or pharmaceutically acceptable salts thereof include a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol (PEG) copolymer. In some embodiments, at least a portion of allylvalerolactone residues within the copolymer are crosslinked with a crosslinker. In some embodiments, the compound has a polydispersity index of less than or equal to 1.5. In one aspect, a method is described herein, comprising: (a) polymerizing valerolactone residues, allylvalerolactone, and polyethylene glycol residues in the presence of a non-metal catalyst via a ring opening polymerization to produce a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer; (b) crosslinking the poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer with a crosslinker; and (c) loading a drug into the crosslinked copolymer.

Abstract: Compositions and methods for the preparation of nanoemulsion from oils are disclosure. These nanoemulsions can be produced without the addition of exogenous surfactants or emulsifiers and can be useful as carriers for active ingredients.

Abstract: The present invention is directed to a polymer platform comprising poly(L-lysine succinylated) which specifically targets scavenger receptor A1. This platform may be used to conjugate different types of drugs to the polymer for treatment of specific diseases or conditions in a patient. The resulting conjugates display moderate stability or controlled drug release, and allows for delivery and release of drugs and other therapeutic moieties to tissues/cells that express scavenger receptor A1 in a controlled manner.

Abstract: The present disclosure relates to controlling drug release in cross-linked poly(valerolactone) based matrices. In one aspect, the compounds or pharmaceutically acceptable salts thereof include a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol (PEG) copolymer. In some embodiments, at least a portion of allylvalerolactone residues within the copolymer are crosslinked with a crosslinker. In some embodiments, the compound has a polydispersity index of less than or equal to 1.5. In one aspect, a method is described herein, comprising: (a) polymerizing valerolactone residues, allylvalerolactone, and polyethylene glycol residues in the presence of a non-metal catalyst via a ring opening polymerization to produce a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer; (b) crosslinking the poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer with a crosslinker; and (c) loading a drug into the crosslinked copolymer.

Abstract: The present invention is directed to a polymer platform comprising poly(L-lysine succinylated) which specifically targets scavenger receptor A1. This platform may be used to conjugate different types of drugs to the polymer for treatment of specific diseases or conditions in a patient. The resulting conjugates display moderate stability or controlled drug release of about 3-80 hours in plasma, and allow delivery and release of drugs and other therapeutic moieties to tissues/cells that express scavenger receptor A1 in a controlled manner.

Abstract: Disclosed are crosslinked particles (e.g., microparticles) that are capable of storing and releasing drugs. The particles can be macroparticles, microparticles, or nanoparticles and can be composed of polyester backbones. The particles can be loaded with a drug. The particles can degrade in vivo to release the drug. The particles can be prepared by crosslinking functionalized polyester backbones and loaded with a given drug. The particles of the present disclosure can be injected with a syringe. In some embodiments, the particles of the present disclosure are administered in connection with a surgery and release the drug after the site of the surgery for a period of 1-6 months.